About 16% of lesions were missed, and approximately 5% of clinically important prostate cancers (>5 mm, Gleason score > 3+3) were underestimated on MP MRI, according to Baris Turkbey, MD, of the Molecular Imaging Program at the National Cancer Institute in Bethesda, Maryland, and colleagues. Overall, prostate cancer size was underestimated by at least 30% in eight (8%) of 100 patients. Their study was published online October 20 in Radiology.
Almost twice as sensitive as TRUS-biopsy for detecting aggressive prostate cancer
Published online before print February 16, 2016, DOI: 10.1200/JCO.2015.65.7759 Ronald C. Chen, R. Bryan Rumble, D. Andrew Loblaw, Antonio Finelli, Behfar Ehdaie, Matthew R. Cooperberg, Scott C. Morgan, Scott Tyldesley, John J. Haluschak, Winston Tan, Stewart Justman, and Suneil Jain
Source: Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement | ASCO Institute For Quality
The new study shows an association between higher blood levels of omega-3 and prostate cancer incidence, nothing more. Despite the inclination to burn them in effigy, the authors themselves claimed nothing more than that. Specific assertions about fish oil supplements are products of media distortion, a problem that routinely bedevils the delivery of medical news — and an issue my next column will show to be a life-and-death concern for us all.
These approaches to managing serial PSA levels reflect either a fundamental misunderstanding of — or an unwillingness to acknowledge — PSA’s limitations as a marker for early prostate cancer. Observational studies show clearly that PSA levels fluctuate spontaneously, moving above or below whatever threshold clinicians deem worrisome. In addition, random biopsies can detect prostate cancer in 12% of men with PSA levels below 2 ng per milliliter and in 25% of men with levels between 2.1 and 4.0 ng per milliliter4; the latter figure approximates the prevalence often reported for men with levels between 4.0 and 10.0 ng per milliliter. When the PSA goes up — for example, from 3.0 to 4.0 ng per milliliter — and triggers a biopsy that reveals cancer, clinicians refer to “PSA-detected cancer.” But many of these cancers are not really detected by PSA screening; they are incidental findings against a background of randomly fluctuating PSA levels and an age-related increase in prostate-cancer incidence.
I realize today is the day after Thanksgiving and I’m working. But medicine never stops and a life underwriter has to do what a life underwriter does on her day off. Read medical journals! Check out these articles from NEJM. Time to change our PSA underwriting guidelines? I think so. Call me if you need help with this. I have a mortgage, one undergraduate, and one medical student to support.
Speaking of the medical student I was trapped this Thanksgiving in the car and listened to over five hours of lectures on neurology and hematology during the ride. To tell the truth, I enjoyed the lectures.
Medicine never takes a day off nor do expert life underwriters.
The results, published in the Public Library of Science (PLoS) ONE journal, showed that MSMB is found at significantly lower levels in the urine of men diagnosed with prostate cancer than those without the disease. They also showed men with aggressive tumors were also likely to have lower levels of the protein in their urine.
Androgen deprivation therapy (ADT) for prostate cancer can exacerbate cardiac risk factors and may increase the risk of heart attack and cardiac death, according to an advisory supported by four medical organizations.
So my pot a day habit is GOOD!